Pharmacological Approach to Gastric Acid Suppression: Past, Present, and Future

Lászlo Herszényi, Tamás Bakucz, Loránd Barabás, Zsolt Tulassay

Research output: Contribution to journalArticle

Abstract

Less than 2 centuries have elapsed since the identification of hydrochloric acid in the stomach. The clarification of the molecular mechanisms allowed the effective therapeutic suppression of gastric acid secretion. The spectacular advances in the treatment of acid-related disorders represent a synthesis of the contributions of several brilliant pharmacologists, basic scientists, and clinical physicians. Effective gastric acid suppressive therapy has dramatically improved the therapy and outcome of acid-related disorders. The introduction of proton pump inhibitors (PPIs) in clinical practice has significantly changed the medical management of upper gastrointestinal disorders. PPIs represent the "gold-standard" therapy in acid-related disorders. However, some challenges persist in the therapy of acid related diseases, including management of patients who respond inadequately to PPI therapy, more effective gastroprotection, or more powerful antisecretory treatment for the eradication of Helicobacter pylori infection. New antisecretory drugs are currently being developed and investigated to further provide a more effective and profound gastric acid secretion inhibition. The major advance has been the development of acid pump-antagonists, the potassium channel acid blocking drugs (-P-CABs). Long-term studies comparing P-CABs with PPIs will help to define the exact place and safety profile of this class of drug in the management of acid-related disorders.

Original languageEnglish
JournalDigestive Diseases
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Gastric Acid
Pharmacology
Proton Pump Inhibitors
Acids
Therapeutics
Pharmaceutical Preparations
Hydrochloric Acid
Potassium Channels
Helicobacter Infections
Disease Management
Helicobacter pylori
Gold
Stomach
Physicians
Safety

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Pharmacological Approach to Gastric Acid Suppression : Past, Present, and Future. / Herszényi, Lászlo; Bakucz, Tamás; Barabás, Loránd; Tulassay, Zsolt.

In: Digestive Diseases, 01.01.2019.

Research output: Contribution to journalArticle

@article{86349ae912d64aafb64a72f4b2a84eeb,
title = "Pharmacological Approach to Gastric Acid Suppression: Past, Present, and Future",
abstract = "Less than 2 centuries have elapsed since the identification of hydrochloric acid in the stomach. The clarification of the molecular mechanisms allowed the effective therapeutic suppression of gastric acid secretion. The spectacular advances in the treatment of acid-related disorders represent a synthesis of the contributions of several brilliant pharmacologists, basic scientists, and clinical physicians. Effective gastric acid suppressive therapy has dramatically improved the therapy and outcome of acid-related disorders. The introduction of proton pump inhibitors (PPIs) in clinical practice has significantly changed the medical management of upper gastrointestinal disorders. PPIs represent the {"}gold-standard{"} therapy in acid-related disorders. However, some challenges persist in the therapy of acid related diseases, including management of patients who respond inadequately to PPI therapy, more effective gastroprotection, or more powerful antisecretory treatment for the eradication of Helicobacter pylori infection. New antisecretory drugs are currently being developed and investigated to further provide a more effective and profound gastric acid secretion inhibition. The major advance has been the development of acid pump-antagonists, the potassium channel acid blocking drugs (-P-CABs). Long-term studies comparing P-CABs with PPIs will help to define the exact place and safety profile of this class of drug in the management of acid-related disorders.",
author = "L{\'a}szlo Hersz{\'e}nyi and Tam{\'a}s Bakucz and Lor{\'a}nd Barab{\'a}s and Zsolt Tulassay",
year = "2019",
month = "1",
day = "1",
doi = "10.1159/000505204",
language = "English",
journal = "Digestive Diseases",
issn = "0257-2753",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Pharmacological Approach to Gastric Acid Suppression

T2 - Past, Present, and Future

AU - Herszényi, Lászlo

AU - Bakucz, Tamás

AU - Barabás, Loránd

AU - Tulassay, Zsolt

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Less than 2 centuries have elapsed since the identification of hydrochloric acid in the stomach. The clarification of the molecular mechanisms allowed the effective therapeutic suppression of gastric acid secretion. The spectacular advances in the treatment of acid-related disorders represent a synthesis of the contributions of several brilliant pharmacologists, basic scientists, and clinical physicians. Effective gastric acid suppressive therapy has dramatically improved the therapy and outcome of acid-related disorders. The introduction of proton pump inhibitors (PPIs) in clinical practice has significantly changed the medical management of upper gastrointestinal disorders. PPIs represent the "gold-standard" therapy in acid-related disorders. However, some challenges persist in the therapy of acid related diseases, including management of patients who respond inadequately to PPI therapy, more effective gastroprotection, or more powerful antisecretory treatment for the eradication of Helicobacter pylori infection. New antisecretory drugs are currently being developed and investigated to further provide a more effective and profound gastric acid secretion inhibition. The major advance has been the development of acid pump-antagonists, the potassium channel acid blocking drugs (-P-CABs). Long-term studies comparing P-CABs with PPIs will help to define the exact place and safety profile of this class of drug in the management of acid-related disorders.

AB - Less than 2 centuries have elapsed since the identification of hydrochloric acid in the stomach. The clarification of the molecular mechanisms allowed the effective therapeutic suppression of gastric acid secretion. The spectacular advances in the treatment of acid-related disorders represent a synthesis of the contributions of several brilliant pharmacologists, basic scientists, and clinical physicians. Effective gastric acid suppressive therapy has dramatically improved the therapy and outcome of acid-related disorders. The introduction of proton pump inhibitors (PPIs) in clinical practice has significantly changed the medical management of upper gastrointestinal disorders. PPIs represent the "gold-standard" therapy in acid-related disorders. However, some challenges persist in the therapy of acid related diseases, including management of patients who respond inadequately to PPI therapy, more effective gastroprotection, or more powerful antisecretory treatment for the eradication of Helicobacter pylori infection. New antisecretory drugs are currently being developed and investigated to further provide a more effective and profound gastric acid secretion inhibition. The major advance has been the development of acid pump-antagonists, the potassium channel acid blocking drugs (-P-CABs). Long-term studies comparing P-CABs with PPIs will help to define the exact place and safety profile of this class of drug in the management of acid-related disorders.

UR - http://www.scopus.com/inward/record.url?scp=85076811609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076811609&partnerID=8YFLogxK

U2 - 10.1159/000505204

DO - 10.1159/000505204

M3 - Article

C2 - 31846972

AN - SCOPUS:85076811609

JO - Digestive Diseases

JF - Digestive Diseases

SN - 0257-2753

ER -